ICON PLC Files 6-K for Q3 2025 Period
Ticker: ICLR · Form: 6-K · Filed: Oct 23, 2025 · CIK: 1060955
Sentiment: neutral
Topics: financial-reporting, 6-K, quarterly-update
TL;DR
ICON PLC dropped its Q3 2025 6-K, check the numbers vs last year.
AI Summary
ICON PLC filed a 6-K report on October 23, 2025, for the period ending September 30, 2025. The filing includes financial data for the third quarter and the first nine months of 2025, comparing it to the same periods in 2024. Specific financial figures like revenue, net income, and earnings per share for these periods are detailed within the report.
Why It Matters
This filing provides investors with updated financial performance data for ICON PLC, crucial for assessing the company's recent operational results and future outlook.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) providing standard financial reporting and does not indicate any unusual or high-risk events.
Key Numbers
- Q3 2025 — Reporting Period (Financial data for the third quarter of 2025 is presented.)
- First Nine Months 2025 — Reporting Period (Financial data for the first nine months of 2025 is presented.)
Key Players & Entities
- ICON PLC (company) — Filer of the report
- 0001628280-25-046120 (other) — Accession Number for the filing
- 20251023 (date) — Filing date
- 20250930 (date) — Period of report
FAQ
What is the filing date of this 6-K report?
The filing date is October 23, 2025.
What period does this 6-K report cover?
The report covers the period ending September 30, 2025.
What is the company's Central Index Key (CIK)?
ICON PLC's CIK is 0001060955.
What is the SIC code for ICON PLC?
The Standard Industrial Classification (SIC) code is 8731, which corresponds to Services-Commercial Physical & Biological Research.
What is the business address of ICON PLC?
The business address is South County Business Park, Leopardstown, Dublin 18, Ireland.
Filing Stats: 4,714 words · 19 min read · ~16 pages · Grade level 16.4 · Accepted 2025-10-23 16:35:45
Key Financial Figures
- $750.0 million — which the Company may repurchase up to $750.0 million of the outstanding ordinary shares of t
- $1.0 billion — f February 18, 2025 to repurchase up to $1.0 billion worth of ordinary shares. During Marc
- $250.0 million — se program for a total consideration of $250.0 million. During June 2025, a further 1,717,181
- $500.0 million — hich the Company could repurchase up to $500.0 million of the outstanding ordinary shares of t
Filing Documents
- iclr-20250930.htm (6-K) — 1336KB
- icon-ex22guarantorschedule.htm (EX-22.1) — 89KB
- 0001628280-25-046120.txt ( ) — 7489KB
- iclr-20250930.xsd (EX-101.SCH) — 56KB
- iclr-20250930_cal.xml (EX-101.CAL) — 75KB
- iclr-20250930_def.xml (EX-101.DEF) — 240KB
- iclr-20250930_lab.xml (EX-101.LAB) — 540KB
- iclr-20250930_pre.xml (EX-101.PRE) — 425KB
- iclr-20250930_htm.xml (XML) — 1154KB
Business
Business ICON is a contract research organization ("CRO"), providing outsourced services on a global basis to pharmaceutical, biotechnology, medical device and government and public health organizations. We specialize in the strategic development, management and analysis of programs that support all stages of the clinical development process, from compound selection to Phase I-IV clinical studies. O ur vision is to be the healthcare intelligence partner of choice by delivering industry leading solutions and best in class performance in clinical development. We believe that we are one of a select group of CROs with the expertise and capability to conduct clinical trials in most major therapeutic areas on a global basis and have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated "full-service" or a "blended-service" solution. At September 30, 2025 we had approximately 39,800 employees in 95 locations in 55 countries. During the nine months ended September 30, 2025 we derived 31.2%, 57.7% and 11.1% of our revenue in the United States, Europe and other regions ("Rest of World") respectively (during the nine months ended September 30, 2024: 37.8%, 50.7% and 11.5% respectively). We began operations in 1990 and have expanded our business through organic growth, together with a number of strategic acquisitions to enhance our capabilities and expertise in certain areas of the clinical development process. We are incorporated in Ireland and our principal executive office is located at: South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Republic of Ireland. The contact telephone number of this office is +353-1-291-2000. Recent developments Executive leadership transition On September 4, 2025, the Company announced that Chief Executive Officer ("CEO"), Dr. Steve Cutler, would retire from his role as CEO effective October 1, 2025 and Mr. Barry Balfe, ICON's Chief Operating Officer ("COO"), would